Cargando…

Serum PD-1 levels measured by ELISA using Nivolumab increased in advanced RCC patients: novel approach to develop companion diagnostics for antibody therapy

Detalles Bibliográficos
Autores principales:	Mizutani, Kosuke, Horie, Kengo, Kato, Taku, Nakane, Keita, Kawakami, Kyojiro, Fujita, Yasunori, Ito, Masafumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Letter to the Editors
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527537/ https://www.ncbi.nlm.nih.gov/pubmed/30515569 http://dx.doi.org/10.1007/s00432-018-2806-2

Ejemplares similares

CD44v8-10 mRNA contained in serum exosomes as a diagnostic marker for docetaxel resistance in prostate cancer patients
por: Kato, Taku, et al.
Publicado: (2020)

Diagnostic potential of serum extracellular vesicles expressing prostate-specific membrane antigen in urologic malignancies
por: Kawakami, Kyojiro, et al.
Publicado: (2021)

Gamma-glutamyltransferase activity in exosomes as a potential marker for prostate cancer
por: Kawakami, Kyojiro, et al.
Publicado: (2017)

Gene therapy of prostate cancer using liposomes containing perforin expression vector driven by the promoter of prostate-specific antigen gene
por: Mizutani, Kosuke, et al.
Publicado: (2022)

Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report
por: Mizutani, Kosuke, et al.
Publicado: (2017)

Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab
por: Mizutani, Kosuke, et al.
Publicado: (2021)

Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC)
por: Bialek, Joanna, et al.
Publicado: (2022)

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
por: Ross-Macdonald, Petra, et al.
Publicado: (2021)

Spontaneous healing of rectal penetration by SpaceOAR(®) hydrogel insertion during permanent iodine-125 implant brachytherapy: A case report
por: Iinuma, Koji, et al.
Publicado: (2019)

Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases
por: Wong, Philip, et al.
Publicado: (2023)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

Utility of robot‐assisted radical cystectomy with intracorporeal urinary diversion for muscle‐invasive bladder cancer
por: Koie, Takuya, et al.
Publicado: (2019)

Defining candidate mRNA and protein EV biomarkers to discriminate ccRCC and pRCC from non-malignant renal cells in vitro
por: Zieren, Richard C., et al.
Publicado: (2021)

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
por: Choueiri, Toni K, et al.
Publicado: (2022)

The accuracy of prostate cancer diagnosis in biopsy-naive patients using combined magnetic resonance imaging and transrectal ultrasound fusion-targeted prostate biopsy
por: Uno, Hiromi, et al.
Publicado: (2021)

A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab
por: Tomioka, Masayuki, et al.
Publicado: (2021)

Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study
por: Iinuma, Koji, et al.
Publicado: (2021)

Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study
por: Maruzzo, Marco, et al.
Publicado: (2022)

Leptomeningeal Carcinomatosis in Urothelial Carcinoma of the Urinary Bladder: A Report of a Patient with a Fulminant Course Who Died of Cancer after Definitive Therapies
por: Tomioka, Masayuki, et al.
Publicado: (2021)

Nivolumab (PD-1 Inhibitor) Induced Exacerbation of Psoriasis
por: George, Anju, et al.
Publicado: (2020)

Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough
por: Mollica, Veronica, et al.
Publicado: (2021)

A New Treatment Landscape for RCC: Association of the Human Microbiome with Improved Outcomes in RCC
por: Piao, Xuan-Mei, et al.
Publicado: (2023)

Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy
por: Jahangir, Mohammadsaleh, et al.
Publicado: (2022)

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
por: Zalba, Sara, et al.
Publicado: (2020)

Preoperative predictive factors of carcinoma in situ in the normal‐appearing mucosa in patients who underwent an initial transurethral resection for non‐muscle‐invasive bladder cancer under white light cystoscopy
por: Iinuma, Koji, et al.
Publicado: (2020)

ALK Gene Translocation in Inflammatory Myofibroblastic Tumor of the Urinary Bladder: A Case Report
por: Takagi, Kimiaki, et al.
Publicado: (2015)

Molecular subtypes and prognosis in RCC
por: Beuselinck, Benoit, et al.
Publicado: (2015)

Open Surgery for Localized RCC
por: Vander Eeckt, Kathy, et al.
Publicado: (2007)

Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
por: Paoluzzi, L., et al.
Publicado: (2016)

Urine Metabolomics for Renal Cell Carcinoma (RCC) Prediction: Tryptophan Metabolism as an Important Pathway in RCC
por: Liu, Xiaoyan, et al.
Publicado: (2019)

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
por: Ornstein, Moshe C., et al.
Publicado: (2019)

A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC)
por: Shah, Ruchitbhai, et al.
Publicado: (2019)

Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
por: Iinuma, Koji, et al.
Publicado: (2021)

An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
por: Tan, Shuguang, et al.
Publicado: (2017)

Soluble PD-L1 as an early marker of progressive disease on nivolumab
por: Mahoney, Kathleen M, et al.
Publicado: (2022)

Untangling ccRCC prognosis with SLINKY
por: Reinfeld, Bradley I., et al.
Publicado: (2017)

The Multifaceted Roles of RCC1 in Tumorigenesis
por: Ren, Xuanqi, et al.
Publicado: (2020)

STARLITE 1: Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC
por: Hasanov, Elshad, et al.
Publicado: (2023)

Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model
por: Yuen, J S P, et al.
Publicado: (2011)

Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors
por: Kaymakcalan, M D, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2frd07ldgh4kfl8snk7tq921th